Medical Crossfire®: Expert Perspectives in Dry Eye Disease – Analyzing DED in the Digital Era and How Emerging Therapies May Shift the Treatment Paradigm

Release Date: April 15, 2021
Expiration Date: April 15, 2022

Activity Overview

The Medical Crossfire™, one of PER’s^® signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the increasing prevalence of dry eye disease, available treatment options, and emerging novel agents with unique mechanisms of action. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with dry eye disease.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Oyster Point Pharma, LLC.

Target Audience

This online educational activity is directed toward ophthalmologists, optometrists, and other health care professionals involved in the treatment of patients with dry eye disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess the impact of increased screen time due to COVID-19 and other factors that may contribute to the development and prevalence of dry eye disease
• Evaluate new mechanisms of action, efficacy, and safety data for emerging therapies seeking indications for dry eye disease
• Apply shared decision-making to ensure treatment approaches that take into account patient preferences and goals

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Chair

David L. Wirta, MD
Principal Investigator
Medical Director
Eye Research Foundation
Ophthalmologist
Oculoplastic Surgeon
Aesthetic Eyecare Institute
Newport Beach, CA

Disclosures: Grant/Research Support: Aerie Pharmaceuticals, Allergan, GreenLight Clinical, Novaliq, Novartis, Ora, Oyster Point Pharma, TearCare.

Faculty

Preeya K. Gupta, MD
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, NC

Disclosures: Consultant: Alcon, Allergan, HanAll Biopharma, Johnson & Johnson Vision, Kala Pharmaceuticals, New World Medical, Novartis, Ocular Therapeutix, Oyster Point Pharma, ReGenTree, Sight Sciences, Sun Pharmaceutical Industries, TearLab, TissueTech, Zeiss.

Michael B. Raizman, MD
Co-Director, Cornea and Cataract Service
New England Eye Center
Associate Professor of Ophthalmology
Director, Cornea and Anterior Segment Service
Department of Ophthalmology, Tufts University School of Medicine
Ophthalmic Consultants of Boston
Boston, MA

Disclosures: Consultant: Alcon, Altacor, Aurinia, Claris, Eyevance Pharmaceuticals, Glaukos, Novartis, Ocular Therapeutix, Oculis, Oyster Point Pharma, Sun Ophthalmics.

Vance Thompson, MD
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Founder
Vance Thompson Vision
Refractive & Cataract Surgeon
Sioux Falls, SD

Disclosures: Consultant/Advisor: AcuFocus, Alcon, Allergan, Allotex, Avellino, Avisi Technologies, Inc, Bausch + Lomb, BRIM Biotechnology, Inc, Carl Zeiss Meditec, Centricity Vision, Conjtac, CSO, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical Inc, Eyedetec, EyeGate Pharma, FemtoVision, Forsight Robotics, Glaukos, Healthe, Imprimis, iVeena, Johnsonand & Johnson Vision, Leica Microsystems, Melt Pharmaceuticals, Ocular Innovations, OneFocus Vision, Ora, Oyster Point Pharma, Percept, ReFocus Eye Health, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Pharmaceuticals, TearClear, TherOptix, Treehouse Health, Veracity Surgical, Visant Medical, Visus Therapeutics, Vivior AG; Equity Owner: AcuFocus, AI Optics, Allotex, Avellino, Avisi Technologies, Inc, Centricity Vision, Conjtac, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical Inc, Eyedetec, EyeGate Pharma, FemtoVision, Forsight Robotics, Healthe, iVeena, Melt Pharmaceuticals, Ocular Innovations, OneFocus Vision, Oyster Point Pharma, Percept, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Pharmaceuticals, TearClear, TherOptix, Treehouse Health, Veracity Surgical, Visant Medical, Vivior AG; Lecture Fees: AcuFocus, Alcon, Glaukos, Johnson & Johnson Vision; Research: AcuFocus, Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity Vision, Equinox, EyeGate Pharma, Glaukos, Johnson & Johnson Vision, Ora, RxSight, Sight Sciences.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.